Veru q1 loss per share $0.05

Veru continues strong positive sales momentum in fiscal 2020 first quarter; net revenues increase 66%, gross profit up 57%.q1 loss per share $0.05.q1 earnings per share estimate $-0.02 -- refinitiv ibes data.q1 revenue $10.6 million versus refinitiv ibes estimate of $8.8 million.completion of veru-111 phase 1b clinical trial and initiation of phase 2 prostate cancer clinical trial in q2 fy 2020.company will submit an nda for tadfin which is expected in second half of 2020.veru sees zuclomiphene entering pivotal phase 3 clinical trial for treating hot flashes in men with prostate cancer on adt after meeting with fda.
VERU Ratings Summary
VERU Quant Ranking